The story of Viagra, originally marketed by copyright, presents a fascinating case study for investors considering the drug sector. Despite its groundbreaking success and impact of countless in sales, the intellectual property end has opened the door for generic medications, significantly reducing earnings opportunities. This shift raises doubts ab